Título de Especialista em Alergia e Imunologia common mistakes
Título de Especialista em Alergia e Imunologia · Understand the traps and how to avoid them.
Selecting the most sensitive test (e.g., total IgE, skin prick test) as the confirmatory test for a suspected food or drug allergy, instead of an oral challenge or a validated specific IgE assay interpreted against the clinical history.
Candidates memorize test characteristics in isolation and conflate screening sensitivity with diagnostic confirmation; commercial question banks often reward 'most sensitive' as a shortcut.
What to do instead
For each allergen, state the reference-standard test explicitly before answering: double-blind placebo-controlled food challenge for food allergy, drug provocation test for drug allergy, and specific IgE/skin prick only as sensitization markers requiring clinical correlation. Practice writing the pretest probability and the post-test interpretation for each scenario.
Diagnosing primary immunodeficiency based on a single low immunoglobulin level or a low lymphocyte subset without repeating the test, checking age-specific reference ranges, or excluding secondary causes (protein-losing states, nephrotic syndrome, immunosuppressants, prematurity).
Reference ranges vary by age and laboratory, and candidates apply adult cutoffs to infants or ignore transient hypogammaglobulinemia of infancy.
What to do instead
Use a structured checklist: repeat abnormal values after 4-6 weeks, apply age-matched reference intervals, exclude protein loss and drug effects, then confirm with functional testing (specific antibody response to vaccines, switched memory B cells). Memorize the threshold patterns for CVID, XLA, SCID, and transient hypogammaglobulinemia.
Misclassifying a hypersensitivity reaction by Gell-Coombs type, particularly labeling a maculopapular drug eruption or a delayed reaction as immediate/type I, or calling a cytotoxic drug reaction type IV.
The timeline (minutes to hours vs days) is the key discriminator, and candidates skim the vignette for the drug name rather than the onset time.
What to do instead
Before answering, extract the onset latency, the effector mechanism, and the characteristic lesion. Build a table linking each type to its timing, mediators, and classic examples (anaphylaxis, hemolytic anemia, serum sickness, contact dermatitis/SJS-TEN), and rehearse it against timed vignettes.
Choosing epinephrine dose or route incorrectly in anaphylaxis, such as giving intravenous epinephrine as first-line therapy in a stable patient, using an antihistamine or corticosteroid as the initial drug, or withholding epinephrine because of a history of cardiac disease.
Candidates recall that antihistamines treat urticaria and corticosteroids prevent biphasic reactions, and they over-weight contraindications in older patients.
What to do instead
Anchor the algorithm: intramuscular epinephrine 0.01 mg/kg (max 0.5 mg) into the anterolateral thigh is first-line in all age groups, repeated every 5-15 minutes as needed; IV infusion only for refractory shock under monitoring. Antihistamines and steroids are adjuncts, never first-line. Practice the relative-versus-absolute contraindication distinction.
Prescribing a beta-lactam to a patient labeled penicillin-allergic without performing risk stratification, or conversely avoiding all beta-lactams in a patient with a benign delayed rash, rather than using delabeling strategies and graded challenge.
The 'allergy' label in the chart is treated as an immutable fact, and candidates do not distinguish low-risk delayed benign rashes from severe cutaneous adverse reactions.
What to do instead
Apply a risk framework: identify severe reactions (anaphylaxis, SJS/TEN, DRESS, AGEP, organ involvement) as high-risk requiring avoidance and specialist evaluation, and low-risk delayed rashes as candidates for direct oral challenge or delabeling. Know the cross-reactivity data for cephalosporins and carbapenems and when skin testing adds value.
Interpreting a positive skin prick test or specific IgE as proof of clinical allergy without considering sensitization versus allergy, test performance in the relevant population, or the effect of antihistamines and dermographism on skin testing.
Candidates equate a positive result with disease and forget that positive predictive value depends on prevalence and the patient's history.
What to do instead
Always compute the post-test probability using the pretest probability from the history. State the criteria for a positive skin test (wheal ≥3 mm above negative control), the washout period for antihistamines, and the role of component-resolved diagnostics in cross-reactivity. Practice questions that hinge on a positive test in a patient with no reaction history.
Mismanaging asthma severity and step therapy, such as escalating to a high-dose inhaled corticosteroid before confirming adherence and inhaler technique, or failing to recognize that a patient on a leukotriene modifier or LABA alone is undertreated.
Candidates memorize step numbers but skip the prerequisite assessment of adherence, technique, and comorbidity that determines whether a step change is appropriate.
What to do instead
Use a fixed sequence: confirm diagnosis, assess control with a validated tool, check adherence and technique, treat comorbidities (rhinitis, reflux, obesity, OSA), then step up or down. Remember that a LABA is never used as monotherapy in asthma and that ICS-formoterol is preferred as reliever in the current strategy for many patients.
Confusing the indications and timing of allergen immunotherapy, such as starting subcutaneous immunotherapy during an acute asthma exacerbation, in an uncontrolled asthmatic, or in a patient with an autoimmune disease, or misstating the duration of therapy.
Candidates learn that immunotherapy is disease-modifying and overlook the absolute contraindications and the 3-5 year treatment duration.
What to do instead
Memorize the contraindication list (uncontrolled asthma, active autoimmune disease, malignancy, beta-blocker use, pregnancy initiation) and the rule that immunotherapy continues rather than starts during pregnancy. Know that clinical benefit requires 3-5 years and that systemic reactions are managed with epinephrine.
Applying adult dosing and formulations to pediatric patients, for example using adult epinephrine autoinjector strengths, adult antihistamine doses, or asthma inhaler regimens without weight-based adjustment and device selection.
Candidates study adult protocols and assume linear scaling; pediatric device availability and weight thresholds are less familiar.
What to do instead
Build a pediatric dosing reference for epinephrine (0.01 mg/kg IM, autoinjector 0.15 mg for 15-30 kg and 0.3 mg above 30 kg), antihistamines, and corticosteroids. Pair each with the appropriate spacer or face mask and rehearse weight-band questions.
Failing to recognize red-flag syndromes and their urgency, such as missing DRESS, Stevens-Johnson syndrome/toxic epidermal necrolysis, or hereditary angioedema in a patient with angioedema unresponsive to antihistamines and epinephrine.
Early presentations overlap with benign rashes or allergic angioedema, and candidates anchor on the common diagnosis.
What to do instead
Learn the discriminating features: DRESS (fever, eosinophilia, facial edema, organ involvement, 2-8 week latency), SJS/TEN (mucosal involvement, Nikolsky sign, body surface area detachment), and HAE (no urticaria, family history, C1 inhibitor deficiency, bradykinin-mediated, unresponsive to epinephrine). Practice recognizing these from a short vignette and stating the immediate management step.